{"id":"W1478180867","doi":"10.1016/j.ejca.2015.06.072","title":"P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Monoclonal antibody; Melanoma; Antibody; Monoclonal; Oncology; Internal medicine; Cancer research; Immunotherapy; Immunology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001155104,0.0001584358,0.0004798611,0.0001143933,0.00002804172,0.00001382452,0.0002901382,0.00003633901,0.0001373386],"category_scores_gemma":[0.0001059819,0.0000871303,0.0002104831,0.0003242378,0.0002094354,0.0001006026,0.00004805033,0.0004123819,0.000005979316],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001174246,"about_ca_system_score_gemma":0.0005604422,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004697473,"about_ca_topic_score_gemma":0.00001624589,"domain_scores_codex":[0.9976503,0.0004515445,0.0009360085,0.0001558553,0.0006030293,0.0002032911],"domain_scores_gemma":[0.9982859,0.00004514381,0.0007541881,0.0002719769,0.0004800227,0.0001627046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01736534,0.0005211893,0.9549696,0.0000158865,0.0003644721,0.0001375182,0.0003867612,0.00005020535,0.0009228268,0.000003559729,0.004933164,0.0203295],"study_design_scores_gemma":[0.02446861,0.001586377,0.9452325,0.0004857153,0.0001224081,0.00005382365,0.00005600974,0.00001246367,0.0005269023,0.000001721068,0.02734849,0.0001050471],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943715,0.001527864,0.00001852769,0.0008672953,0.0007172403,0.0002008759,0.00001427265,0.000006174835,0.002276188],"genre_scores_gemma":[0.9985706,0.0002575777,0.000137905,0.0004777098,0.0003176279,3.833382e-7,0.000006318032,0.00003589852,0.0001960455],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02241533,"threshold_uncertainty_score":0.355307,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03157796465360636,"score_gpt":0.3341233880962667,"score_spread":0.3025454234426604,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}